Effects of a Hypotension-Avoidance Versus a Hypertension-Avoidance Strategy on Neurocognitive Outcomes After Noncardiac Surgery. Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • View All
  •  

abstract

  • BACKGROUND: Perioperative hemodynamic abnormalities have been associated with neurocognitive outcomes after noncardiac surgery. OBJECTIVE: To compare the effects of perioperative hypotension-avoidance versus hypertension-avoidance strategies on delirium and 1-year cognitive decline after noncardiac surgery. DESIGN: Randomized controlled trial. (ClinicalTrials.gov: NCT03505723). SETTING: 54 centers, 19 countries. PARTICIPANTS: 2603 high-vascular-risk patients undergoing noncardiac surgery, receiving 1 or more chronic antihypertensive medications (mean age, 70 years). INTERVENTION: In the hypotension-avoidance strategy, the intraoperative mean arterial pressure (MAP) target was 80 mm Hg or greater; before and for 2 days after surgery, renin-angiotensin-aldosterone system inhibitors were withheld, and other chronic antihypertensive medications were administered for systolic blood pressures of 130 mm Hg or greater following an algorithm. In the hypertension-avoidance strategy, the intraoperative MAP target was 60 mm Hg or greater; all chronic antihypertensive medications were continued perioperatively. MEASUREMENTS: Delirium on postoperative day 1 to 3 (primary outcome); decline of 2 points or more at the Montreal Cognitive Assessment (MoCA) 1 year after surgery compared with baseline (secondary outcome). RESULTS: 95 of 1310 patients (7.3%) in the hypotension-avoidance and 90 of 1293 patients (7.0%) in the hypertension-avoidance group had delirium (relative risk [RR], 1.04 [95% CI, 0.79 to 1.38]). Among 701 patients who completed 1-year MoCA (full or telephone version), 129 of 347 (37.2%) in the hypotension-avoidance and 117 of 354 (33.1%) in the hypertension-avoidance group had a decline of 2 or more points (RR, 1.13 [CI, 0.92 to 1.38]). Nineteen percent in the hypotension-avoidance and 27% in the hypertension-avoidance strategy had hypotension requiring an intervention (RR, 0.63 [CI, 0.52 to 0.76]), mostly intraoperatively; only 5%, in both groups, had hypotension postoperatively. LIMITATION: The COVID-19 pandemic challenged site participation in the substudy; although large, the sample size was lower than expected. CONCLUSION: There was no evidence of a difference in neurocognitive outcomes between the hypotension-avoidance and hypertension-avoidance strategies. PRIMARY FUNDING SOURCE: Canadian Institutes of Health Research, Canada; National Health and Medical Research Council, Australia; Research Grant Council, Hong Kong SAR, China.

authors

  • Marcucci, Maura
  • Chan, Matthew TV
  • Painter, Thomas W
  • Efremov, Sergey
  • Aguado, Hector J
  • Astrakov, Sergey V
  • Kleinlugtenbelt, Ydo V
  • Patel, Ameen
  • Cata, Juan P
  • Amir, Mohammed
  • Kirov, Mikhail
  • Leslie, Kate
  • Duceppe, Emmanuelle
  • Borges, Flavia K
  • de Nadal, Miriam
  • Tandon, Vikas
  • Landoni, Giovanni
  • Likhvantsev, Valery V
  • Lomivorotov, Vladimir
  • Sessler, Daniel I
  • Martínez-Zapata, María José
  • Xavier, Denis
  • Fleischmann, Edith
  • Wang, Chew Yin
  • Meyhoff, Christian S
  • Wittmann, Maria
  • Torres, David
  • Highton, David
  • Jacka, Michael
  • B, Vishwanath
  • Zarnke, Kelly
  • Sidhu, Ravinder Singh
  • Oriani, Giorgio
  • Ayad, Sabry
  • Minear, Steven
  • Weaver, Tristan E
  • Ruetzler, Kurt
  • Brusasco, Claudia
  • Parlow, Joel L
  • Maxwell, Elizabeth
  • Miller, Scott
  • Mrkobrada, Marko
  • Bhatt, Keyur Suresh Chandra
  • Rahate, Prashant
  • Kowark, Ana
  • De Blasio, Giuseppe
  • Ofori, Sandra N
  • Conen, David
  • Srinathan, Sadeesh
  • Szczeklik, Wojciech
  • Jayaram, Raja
  • Ellerkmann, Richard K
  • Momeni, Mona
  • Copland, Ingrid
  • Vincent, Jessica
  • Balasubramanian, Kumar
  • Li, Zhuoru
  • Wang, Michael Ke
  • Li, Deyang
  • McGillion, Michael H
  • Kurz, Andrea
  • Sharma, Mukul
  • Short, Timothy G
  • Devereaux, Philip
  • cogPOISE-3 Trial Investigators and Study Groups

publication date

  • June 3, 2025